Amgen Inc. v. Sanofi

20-1074 | U.S. Court of Appeals, Federal Circuit

Interested in this case?

Request a Demo Track this case, and find millions of cases like it, let us show you how.
Filed Oct. 24, 2019
Terminated Feb. 11, 2021
Judges MOORE, NEWMAN, LOURIE, DYK, O’MALLEY, REYNA, TARANTO, CHEN, HUGHES, STOLL, and PROST
Nature of Suit 830 Patent
Original Case 1:14-cv-01317
Last Updated: 1 year, 9 months ago Show Interactive Timeline
Filing Date # Docket Text
5/18/2023Opinion filed by the U.S. Supreme Court on 05/18/2023 in No. 21-757. The judgment or decision is affirmed. [924429] [MVH] [Entered: 05/18/2023 03:54 PM]
2/14/2023Record sent to the U.S. Supreme Court on 02/14/2023. [904107] [JCP] [Entered: 02/14/2023 12:32 PM]
2/3/2023Letter from the U.S. Supreme Court requesting the entire record and briefs. [901880] [JCP] [Entered: 02/03/2023 03:28 PM]
1/10/20231632 of 3 boxes containing Appellant's visual aid returned by Hand delivery. [895872] [MVH] [Entered: 01/10/2023 12:37 PM]
11/4/2022The petition for writ of certiorari, No. 21-757, filed on 11/18/2021, was Granted on 11/04/2022. [884761] [MVH] [Entered: 11/17/2022 03:06 PM]
11/22/2021
  • Motion
Petition for writ of certiorari filed on 11/18/2021 in the U.S. Supreme Court. No.: 21-757, Amgen Inc. v. Sanofi. [814653] [JCP] [Entered: 11/24/2021 08:14 AM]
6/28/2021Mandate issued to the United States District Court for the District of Delaware. Service as of this date by the Clerk of Court. [782841] [MVH] [Entered: 06/28/2021 10:22 AM]
6/21/2021
  • Motion for RehearingDenied
ORDER filed denying petition for rehearing en banc [136] filed by Amgen USA, Inc., Amgen Inc. and Amgen Manufacturing, Limited. Lourie, Circuit Judge, with whom Prost and Hughes, Circuit Judges, join, authored a separate opinion on the denial of the petition for panel rehearing. By: Per Curiam. Service as of this date by the Clerk of Court. [781218] [MJL] [Entered: 06/21/2021 09:48 AM]
5/28/2021
  • Response
RESPONSE of Appellees Sanofi, Aventisub LLC, Sanofi-Aventis U.S. LLC and Regeneron Pharmaceuticals Inc. to Doc No. [136]. Service: 05/28/2021 by email. [777688] [20-1074] [Matthew Wolf] [Entered: 05/28/2021 04:37 PM]
5/3/202115718 paper copies of Doc. No. [156] received from Amici Curiae Bristol-Myers Squibb Company, Corning Incorporated and Merck Sharp & Dohme Corp.. [772621] [VDW] [Entered: 05/03/2021 04:09 PM]
4/29/2021AMICUS BRIEF FILED on Petition by Biogen Inc., Bristol-Myers Squibb Company, Corning Incorporated, and Merck Sharp & Dohme Corp. Service: 04/28/2021 by email. [772144] [MJL] [Entered: 04/29/2021 03:59 PM]
4/29/2021AMICUS BRIEF FILED on Petition by GlaxoSmithKline plc. Service: 04/28/2021 by email. [772143] [MJL] [Entered: 04/29/2021 03:58 PM]
4/29/2021AMICUS BRIEF FILED on Petition by Ann Bartow, Timothy Richard Holbrook, et al ("Intellectual Property Professors"). Service: 04/28/2021 by email. [772142] [MJL] [Entered: 04/29/2021 03:57 PM]
4/29/2021
  • Motion to File BriefGranted
ORDER filed. The motions for leave to file briefs as amici curiae ([145], [149], [152]) are granted. The motions to withdraw counsel [146] and for leave to file an entry of appearance for new counsel [152] are granted. By: Per Curiam. Service as of this date by the Clerk of Court. [772136] [MJL] [Entered: 04/29/2021 03:47 PM]
4/28/2021
  • Motion
MOTION of Biogen Inc.; Corning Incorporated Amici Curiae Bristol-Myers Squibb Company and Merck Sharp & Dohme Corp. for leave to file entry of appearance(s) for Jeffrey P. Kushan; Steven J. Horowitz; Sue Wang, for leave to file an amicus curiae brief. Service: 04/28/2021 by email. [771910] [20-1074] [Jeffrey Kushan] [Entered: 04/28/2021 06:38 PM]
4/28/2021Certificate of Interest for Amici Curiae Bristol-Myers Squibb Company and Merck Sharp & Dohme Corp. Biogen Inc.; Corning Incorporated. Service: 04/28/2021 by email. [771907] [20-1074] [Jeffrey Kushan] [Entered: 04/28/2021 06:29 PM]
4/28/2021Entry of appearance for Jeffrey P. Kushan; Steven J. Horowitz; Sue Wang as counsel for Amici Curiae Bristol-Myers Squibb Company and Merck Sharp & Dohme Corp. Biogen Inc.; Corning Incorporated. Service: 04/28/2021 by email. [771905] [20-1074] [Jeffrey Kushan] [Entered: 04/28/2021 06:25 PM]
4/28/2021
  • Motion to File Brief
MOTION of GlaxoSmithKline plc. for leave to file amicus brief in support of Appellants Amgen Inc., Amgen Manufacturing, Ltd., and Amgen USA, Inc. on petition for en banc rehearing [136]. Service: 04/28/2021 by email. [771828] [20-1074] [John Desmarais] [Entered: 04/28/2021 03:44 PM]
4/28/2021Certificate of Interest for GlaxoSmithKline plc.. Service: 04/28/2021 by email. [771820] [20-1074] [John Desmarais] [Entered: 04/28/2021 03:28 PM]
4/28/2021Entry of appearance for John M. Desmarais; Todd L. Krause; Eliyahu Balsam as counsel for GlaxoSmithKline plc.. Service: 04/28/2021 by email. [771818] [20-1074] [John Desmarais] [Entered: 04/28/2021 03:26 PM]
4/28/2021
  • Motion
MOTION of Amici Curiae Bristol-Myers Squibb Company and Merck Sharp & Dohme Corp. to withdraw counsel Jorge A. Goldstein, Eldora L. Ellison, Kristina Caggiano Kelly, and William H. Milliken. Service: 04/28/2021 by email. [771795] [20-1074] [Kristina Caggiano Kelly] [Entered: 04/28/2021 02:44 PM]
4/28/2021
  • Motion
MOTION of Intellectual Property Professors (Amici Curiae) for leave to file an amicus curiae brief. Service: 04/28/2021 by email. [771714] [20-1074] [Mark Lemley] [Entered: 04/28/2021 01:00 PM]
4/28/2021Certificate of Interest for Intellectual Property Professors (Amici Curiae). Service: 04/28/2021 by email. [771710] [20-1074] [Mark Lemley] [Entered: 04/28/2021 12:55 PM]
4/28/2021Entry of appearance for Mark A. Lemley as counsel for Intellectual Property Professors (Amici Curiae). Service: 04/28/2021 by email. [771709] [20-1074] [Mark Lemley] [Entered: 04/28/2021 12:52 PM]
4/20/2021
  • Order
ORDER filed granting Sanofi, Aventisub LLC, Regeneron Pharmaceuticals Inc. and Sanofi-Aventis U.S. LLC's motion [141] to extend time to file a response to the petition for rehearing en banc by 29 days, until 05/28/2021. By: Per Curiam. Service as of this date by the Clerk of Court. [770067] [JCP] [Entered: 04/20/2021 05:07 PM]
4/20/2021MOTION of Appellees Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi and Sanofi-Aventis U.S. LLC to extend the time to file a response to the Petition for Rehearing En Banc until 05/28/2021. Service: 04/20/2021 by email. [769932] [20-1074] [Matthew Wolf] [Entered: 04/20/2021 12:49 PM]
4/20/2021Amended Certificate of Interest for Appellees Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi and Sanofi-Aventis U.S. LLC. Service: 04/20/2021 by email. [769929] [20-1074] [Matthew Wolf] [Entered: 04/20/2021 12:36 PM]
4/20/2021NOTICE OF NON-COMPLIANCE: The submission of Appellees Aventisub LLC, Regeneron Pharmaceuticals Inc., et al., Motion [138], is not in compliance with the rules of this court (see attached). Compliant document due 04/27/2021. Unless ordered otherwise, the deadline for any responsive filing runs from service of the original version. Service as of this date by the Clerk of Court. [769793] [MJL] [Entered: 04/20/2021 08:21 AM]
4/19/2021
  • Motionby Δ
MOTION of Appellees Sanofi, Aventisub LLC, Regeneron Pharmaceuticals Inc. and Sanofi-Aventis U.S. LLC to extend the time to file a response to the Petition for Rehearing En Banc until 05/28/2021. Service: 04/19/2021 by email. [769769] [20-1074]. This motion is non-compliant. See Doc. No. [139]. [Calvin Shank] [Entered: 04/19/2021 10:34 PM]
4/15/2021The court invites a response from Appellees Aventisub LLC, Regeneron Pharmaceuticals Inc., et al. to the petition [136]. Response due 04/29/2021. Service as of this date by the Clerk of Court. [768881] [MJL] [Entered: 04/15/2021 01:04 PM]
4/14/2021
  • Motion for Rehearingby Π
Petition for en banc rehearing filed by Appellants Amgen Inc., Amgen Manufacturing, Limited and Amgen USA, Inc.. Service: 04/14/2021 by email. [768676] [20-1074] [Jeffrey Lamken] [Entered: 04/14/2021 05:48 PM]
3/8/2021
  • Order
ORDER filed granting Amgen's motion [134] to extend the time to file a petition for rehearing by 30 days, until 04/14/2021. By: Merits Panel (Per Curiam). Service as of this date by the Clerk of Court. [760809] [MJL] [Entered: 03/08/2021 02:12 PM]
3/5/2021
  • Motionby Π
MOTION of Appellants Amgen Inc., Amgen Manufacturing, Limited and Amgen USA, Inc. to extend the time to file a Combined Petition for Panel Rehearing and Rehearing En Banc until 04/14/2021. Service: 03/05/2021 by email. [760455] [20-1074] [Jeffrey Lamken] [Entered: 03/05/2021 03:47 PM]
2/11/2021
  • Motion for Judgment
JUDGMENT. AFFIRMED. Terminated on the merits after oral argument. COSTS: Costs taxed against Appellant(s). Mandate to issue in due course. For information regarding costs, petitions for rehearing, and petitions for writs of certiorari click here. [755359] [JCP] [Entered: 02/11/2021 10:24 AM]
2/11/2021OPINION filed for the court by Prost, Chief Judge; Lourie, Circuit Judge and Hughes, Circuit Judge. Precedential Opinion. [755357] [JCP] [Entered: 02/11/2021 10:23 AM]
12/9/2020131Submitted after ORAL ARGUMENT to Panel: Prost, Chief Judge; Lourie, Circuit Judge and Hughes, Circuit Judge.
Arguing counsel: Jeffrey A. Lamken for Amgen USA, Inc., Amgen Inc. and Amgen Manufacturing, Limited and Matthew Wolf for Sanofi, Aventisub LLC, Regeneron Pharmaceuticals Inc. and Sanofi-Aventis U.S. LLC.
Oral Argument Audio available here. [741378] [JAB] [Entered: 12/09/2020 11:16 AM]
11/19/2020Clerk's letter to Appellants Amgen Inc., Amgen Manufacturing, Limited, Amgen USA, Inc. and Appellees Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi and Sanofi-Aventis U.S. LLC regarding Telephonic Argument Orientation. Service as of this date by the Clerk of Court. [736900] [JAB] [Entered: 11/19/2020 11:45 AM]
11/16/2020
  • Responseby Π
Response to notice of oral argument from Appellants Amgen Inc., Amgen Manufacturing, Limited and Amgen USA, Inc.. Service: 11/16/2020 by email. [735819] [20-1074] [Jeffrey Lamken] [Entered: 11/16/2020 01:08 PM]
11/16/2020
  • Response
Response to notice of oral argument from Appellees Sanofi, Sanofi-Aventis U.S. LLC, Regeneron Pharmaceuticals Inc. and Aventisub LLC. Service: 11/16/2020 by email. [735707] [20-1074] [Matthew Wolf] [Entered: 11/16/2020 11:40 AM]
11/10/2020Notice of intent to use visual aids at oral argrument for Appellants Amgen Inc., Amgen Manufacturing, Limited and Amgen USA, Inc.. Service: 11/10/2020 by email. [734719] [20-1074] [Jeffrey Lamken] [Entered: 11/10/2020 10:53 AM]
10/21/2020NOTICE OF TELEPHONIC ORAL ARGUMENT. Panel: 2012G. Case scheduled December 9, 2020. Response to Notice of Oral Argument due: 11/16/2020. The Clerk's Office will provide additional instructions to counsel at least one week ahead of argument. Please review the attached Notice. The response to notice of oral argument form can be found here. The Oral Argument Guide can be found here. Service as of this date by the Clerk of Court. [730582] [JAB] [Entered: 10/21/2020 02:19 PM]
9/1/2020124Supplementary Media Appendix received on CD-ROM from Amgen Inc., Amgen Manufacturing, Limited and Amgen USA, Inc. Number of copies: 4. [727946] [MJL] [Entered: 10/09/2020 03:22 PM]
8/26/20201216 paper copies of the Confidential Joint Appendix in 3 Volumes [106] received from Appellants Amgen Inc., Amgen Manufacturing, Limited and Amgen USA, Inc. [723754]--[Edited 09/22/2020 by JCP to add confidential] [JCP] [Entered: 09/22/2020 05:01 PM]
8/25/20201236 paper copies of the Opening Brief [55] received from Appellants Amgen Inc., Amgen Manufacturing, Limited and Amgen USA, Inc. [723758] [JCP] [Entered: 09/22/2020 05:05 PM]
8/25/20201226 paper copies of the Confidential Reply Brief [104] received from Appellants Amgen Inc., Amgen Manufacturing, Limited and Amgen USA, Inc. [723756] [JCP] [Entered: 09/22/2020 05:02 PM]
8/25/20201206 paper copies of the Amicus Brief [102] received from Amicus Curiae Doctor Stanley D. Liang. [723753] [JCP] [Entered: 09/22/2020 04:59 PM]
8/25/2020117The following conflict dates submitted by Matthew Wolf for Sanofi, Aventisub LLC, Regeneron Pharmaceuticals Inc. and Sanofi-Aventis U.S. LLC have been accepted by the court: 11/02/2020, 11/03/2020, 11/04/2020, 11/05/2020, 11/06/2020. [717324] [JAB] [Entered: 08/25/2020 12:15 PM]
8/25/2020116The following conflict dates submitted by Jeffrey A. Lamken for Amgen USA, Inc., Amgen Inc. and Amgen Manufacturing, Limited have been accepted by the court: 12/07/2020. [717323] [JAB] [Entered: 08/25/2020 12:13 PM]
8/24/20201256 paper copies of Doc. No. [75] received from Appellees Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi and Sanofi-Aventis U.S. LLC. [730310] [VDW] [Entered: 10/20/2020 03:46 PM]
8/24/2020Notice from Appellees Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi and Sanofi-Aventis U.S. LLC regarding conflicts with oral argument. Service: 08/24/2020 by email. [717192] [20-1074] [Matthew Wolf] [Entered: 08/24/2020 09:45 PM]
8/24/2020Notice from Appellants Amgen Inc., Amgen Manufacturing, Limited and Amgen USA, Inc. regarding conflicts with oral argument. Service: 08/24/2020 by email. [717181] [20-1074] [Jeffrey Lamken] [Entered: 08/24/2020 07:41 PM]
8/24/2020113The following conflict dates submitted by Matthew Wolf for Sanofi, Aventisub LLC, Regeneron Pharmaceuticals Inc. and Sanofi-Aventis U.S. LLC have been accepted by the court: 01/06/2021. [717004] [JAB] [Entered: 08/24/2020 02:23 PM]
8/24/2020Notice from Appellees Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC and Aventisub LLC regarding conflicts with oral argument. Service: 08/24/2020 by email. [716992] [20-1074] [Matthew Wolf] [Entered: 08/24/2020 02:14 PM]
8/20/20201196 paper copies of Doc. No. [67] received from Bristol-Myers Squibb Company and Merck Sharp & Dohme Corp. [720119] [MJL] [Entered: 09/08/2020 01:50 PM]
8/19/20201186 paper copies of Doc. No. [91] received from Pfizer Inc. [720036] [MJL] [Entered: 09/08/2020 11:44 AM]
8/17/2020Notice to Advise of Scheduling Conflicts. Arguing counsel must advise of, and show good cause for, any scheduling conflicts during the upcoming court session months listed in the attached notice. The Response to Notice to Advise of Scheduling Conflicts can be found here. The Oral Argument Guide can be found here. [715111] [JAL] [Entered: 08/17/2020 10:10 AM]
8/17/2020110Notice to counsel: The Clerk's Office directs that outstanding paper copies of all briefs and appendices in this case must be submitted on or before August 31, 2020. See Administrative Order No. 20-01 (Mar. 20, 2020). [715110] [JAL] [Entered: 08/17/2020 10:09 AM]
7/30/2020Joint Statement of Compliance with Fed. Cir. R. 33 for Appellants Amgen Inc., Amgen Manufacturing, Limited, Amgen USA, Inc. and Appellees Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi and Sanofi-Aventis U.S. LLC. Service: 07/30/2020 by email. [711464] [20-1074] [Sarah Newman] [Entered: 07/30/2020 08:54 PM]
7/30/2020Certificate of Compliance with Fed. Cir. R. 25.1(c)(2) for Appellants Amgen Inc., Amgen Manufacturing, Limited, Amgen USA, Inc. and Appellees Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi and Sanofi-Aventis U.S. LLC. Service: 07/30/2020 by email. [711463] [20-1074] [Sarah Newman] [Entered: 07/30/2020 08:52 PM]
7/30/2020MODIFIED ENTRY: APPENDIX FILED for Appellants Amgen Inc., Amgen Manufacturing, Limited, and Amgen USA, Inc. Number of Pages: 1304. Service: 07/30/2020 by email. [711462] --[Edited 08/03/2020 by JAL - Compliance review complete] [Sarah Newman] [Entered: 07/30/2020 08:49 PM]
7/30/2020106MODIFIED ENTRY: CONFIDENTIAL APPENDIX FILED for Appellants Amgen Inc., Amgen Manufacturing, Limited, and Amgen USA, Inc. Number of Pages: 1301. Service: 07/30/2020 by email. [711461]--[Edited 08/03/2020 by JAL - Compliance review complete] [Sarah Newman] [Entered: 07/30/2020 08:40 PM]
7/23/2020
  • Replyby Π
MODIFIED ENTRY: REPLY BRIEF FILED for Appellants Amgen Inc., Amgen Manufacturing, Limited, and Amgen USA, Inc. Number of Pages: 35. Service: 07/23/2020 by email. Unless ordered otherwise, any responsive deadline runs from the date of service of this brief. See Fed. Cir. R. 31. [709795] --[Edited 07/29/2020 by JAL - Compliance review complete] [Jeffrey Lamken] [Entered: 07/23/2020 08:33 PM]
7/23/2020104MODIFIED ENTRY: CONFIDENTIAL REPLY BRIEF FILED for Appellants Amgen Inc., Amgen Manufacturing, Limited, and Amgen USA, Inc. Number of Pages: 35. Service: 07/23/2020 by email. [709794]--[Edited 07/29/2020 by JAL - Compliance review complete] [Jeffrey Lamken] [Entered: 07/23/2020 08:30 PM]
7/2/2020Entry of appearance for Stanley D. Liang as counsel for Amicus Curiae Doctor Stanley D. Liang. Service: 07/02/2020 by clerk. [705178] [JAL] [Entered: 07/02/2020 12:29 PM]
7/2/2020AMICUS BRIEF FILED for Amicus Curiae Doctor Stanley D. Liang. Pages: 32. Service: 07/02/2020 by clerk. [705175] [Accepted pursuant to 07/02/2020 order [705102-2]] [JAL] [Entered: 07/02/2020 12:28 PM]
7/2/2020
  • Order
ORDER filed granting [95] the motion. A copy of this order and the motion papers shall be forwarded to the merits panel assigned to this case. Service as of this date by the Clerk of Court. [705172] [LMS] [Entered: 07/02/2020 12:17 PM]
6/23/2020
  • Reply
MODIFIED ENTRY: REPLY of Stanley Liang to response [99]. Service: 06/23/2020 by email. [703174]--[Edited 06/24/2020 by JAL - Reason: to correct filing event] [Stanley Liang] [Entered: 06/23/2020 05:55 PM]
6/19/2020
  • Responseby Π
RESPONSE of Appellants Amgen Inc., Amgen Manufacturing, Limited and Amgen USA, Inc. to the motion [95]. Service: 06/19/2020 by email. [702568] [20-1074] [Jeffrey Lamken] [Entered: 06/19/2020 04:04 PM]
6/17/2020
  • Order
ORDER filed. Any opposition to the motion [95] shall be filed no later than seven days from the date of issuance of this order. Any reply is due no later than three days from the filing of any response. Service as of this date by the Clerk of Court. [701785] [NL] [Entered: 06/17/2020 10:13 AM]
6/16/202097
  • Motion to Extend Time to File BriefGranted
**TEXT ONLY** ORDER granting motion to extend time to file brief [96] filed by Appellants Amgen USA, Inc., Amgen Inc., and Amgen Manufacturing, Limited. The reply brief is due 07/23/2020. Service as of this date by the Clerk of Court. This order has been issued without an attached document and is official and binding. [701464] [JAL] [Entered: 06/16/2020 11:17 AM]
6/15/2020
  • Motion to Extend Time to File Replyby Π
MOTION of Appellants Amgen Inc., Amgen Manufacturing, Limited and Amgen USA, Inc. to extend the time to 07/23/2020 to file the Reply Brief. [Consent: unopposed]. Service: 06/15/2020 by email. [701328] [20-1074] [Jeffrey Lamken] [Entered: 06/15/2020 08:59 PM]
6/12/2020
  • Motion to File Brief
MODIFIED ENTRY: MOTION of Stanley D. Liang for leave to file an amicus curiae brief [Consent: opposed]. Service: 06/12/2020 by email. [700902]--[Edited 06/16/2020 by JAL - Reason: to correct filing event] [Stanley Liang] [Entered: 06/12/2020 04:58 PM]
6/9/2020Certificate of Interest for Amicus Curiae Pfizer Inc.. Service: 06/09/2020 by email. [700100] [20-1074] [Amit Thakore] [Entered: 06/09/2020 01:57 PM]
6/9/202093Notice to counsel for Amicus Curiae Pfizer Inc.: The record of this case indicates that the Certificate of Interest has not been separately filed from the brief. Please file the document promptly. Service as of this date by the Clerk of Court. [700090] [JAL] [Entered: 06/09/2020 01:21 PM]
6/8/2020MODIFIED ENTRY: CORRECTED AMICUS BRIEF FILED for Amicus Curiae Eli Lilly and Company. Pages: 27. Service: 06/08/2020 by email. [699930]--[Edited 06/09/2020 by JAL - Compliance review complete] [Duane Marks] [Entered: 06/08/2020 04:59 PM]
6/8/2020MODIFIED ENTRY: AMICUS BRIEF FILED for Amicus Curiae Pfizer Inc. Pages: 26. Service: 06/08/2020 by email. [699914]--[Edited 06/09/2020 by JAL - Compliance review complete] [Amit Thakore] [Entered: 06/08/2020 04:21 PM]
6/8/2020Entry of appearance for Jeffrey N. Myers as of counsel for Amicus Curiae Pfizer Inc.. Service: 06/08/2020 by email. [699910] [20-1074] [Amit Thakore] [Entered: 06/08/2020 04:15 PM]
6/8/2020Entry of appearance for Dimitrios Drivas as of counsel for Amicus Curiae Pfizer Inc.. Service: 06/08/2020 by email. [699909] [20-1074] [Amit Thakore] [Entered: 06/08/2020 04:12 PM]
6/8/2020Entry of appearance for Elizabeth Chang as of counsel for Amicus Curiae Pfizer Inc.. Service: 06/08/2020 by email. [699908] [20-1074] [Amit Thakore] [Entered: 06/08/2020 04:10 PM]
6/8/2020Entry of appearance for Amit H. Thakore as principal counsel for Amicus Curiae Pfizer Inc.. Service: 06/08/2020 by email. [699906] [20-1074] [Amit Thakore] [Entered: 06/08/2020 04:08 PM]
6/8/2020NOTICE OF NON-COMPLIANCE: The submissions of Stanley D. Liang, Amicus Brief and Entry of Appearance - S. Liang [81], [82], are not in compliance with the rules of this court (see attached). Compliant documents are due on 06/15/2020. Service as of this date by the Clerk of Court. [699780] [JAL] [Entered: 06/08/2020 10:54 AM]
6/8/2020NOTICE OF NON-COMPLIANCE: The submission of Amicus Curiae Eli Lilly and Company, Amicus Brief [84], is not in compliance with the rules of this court (see attached). Compliant document is due on 06/15/2020. Service as of this date by the Clerk of Court. [699777] [JAL] [Entered: 06/08/2020 10:44 AM]
6/5/2020FILED from Eli Lilly and Company Title: AMICUS CURIAE BRIEF. Service: 06/05/2020 by email. [699622] [20-1074] This document is non-compliant. See Doc. No.[85] [Duane Marks] [Entered: 06/05/2020 02:26 PM]
6/5/2020Entry of appearance for Tonya L. Combs as of counsel for Eli Lilly and Company. Service: 06/05/2020 by email. [699618] [20-1074] [Tonya Combs] [Entered: 06/05/2020 02:22 PM]
6/5/2020Entry of appearance for Stanley D Liang as principal counsel for Stanley D Liang. Service: 05/05/2020 by email. [699550] [20-1074] This document is non-compliant. See Doc. No.[86] [Stanley Liang] [Entered: 06/05/2020 12:27 PM]
6/5/2020FILED from Stanley D Liang. Title: AMICUS CURIAE BRIEF. Service: 06/05/2020 by email. [699547] [20-1074] This document is non-compliant. See Doc. No.[86] [Stanley Liang] [Entered: 06/05/2020 12:24 PM]
6/5/2020Entry of appearance for Mark Stewart as of counsel for Eli Lilly and Company. Service: 06/05/2020 by email. [699445] [20-1074] [Mark Stewart] [Entered: 06/05/2020 10:12 AM]
6/5/2020Entry of appearance for Gilbert Voy as of counsel for Eli Lilly and Company. Service: 06/05/2020 by email. [699442] [20-1074] [Gilbert Voy] [Entered: 06/05/2020 09:57 AM]
6/5/2020Certificate of Interest for Eli Lilly and Company. Service: 06/05/2020 by email. [699436] [20-1074] [Duane Marks] [Entered: 06/05/2020 09:48 AM]
6/5/2020Entry of appearance for Duane C. Marks as principal counsel for Eli Lilly and Company. Service: 06/05/2020 by email. [699431] [20-1074] [Duane Marks] [Entered: 06/05/2020 09:44 AM]
6/2/2020MODIFIED ENTRY: CORRECTED RESPONSE BRIEF FILED for Appellees Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, and Sanofi-Aventis U.S. LLC. Number of Pages: 63. Service: 06/02/2020 by email. Unless ordered otherwise, any responsive deadline runs from the date of service of this brief. See Fed. Cir. R. 31. [698784] --[Edited 06/03/2020 by JAL - Compliance review complete] [Calvin Shank] [Entered: 06/02/2020 09:39 PM]
6/2/202075MODIFIED ENTRY: CORRECTED CONFIDENTIAL RESPONSE BRIEF FILED for Appellees Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, and Sanofi-Aventis U.S. LLC. Number of Pages: 63. Service: 06/02/2020 by email. [698782]--[Edited 06/03/2020 by JAL - Compliance review complete] [Calvin Shank] [Entered: 06/02/2020 09:31 PM]
6/2/2020NOTICE OF NON-COMPLIANCE: The submissions of Appellees Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, and Sanofi-Aventis U.S. LLC, Response Brief (Confidential and Non-Confidential) [72], [73], are not in compliance with the rules of this court (see attached). Compliant documents are due on 06/09/2020. Service as of this date by the Clerk of Court. [698595] [JAL] [Entered: 06/02/2020 11:43 AM]
6/1/2020FILED from Appellees Sanofi, Aventisub LLC, Regeneron Pharmaceuticals Inc. and Sanofi-Aventis U.S. LLC. Title: RESPONSE BRIEF. Service: 06/01/2020 by email. [698415] [20-1074] This document is non-compliant. See Doc. No.[74] [Calvin Shank] [Entered: 06/01/2020 07:26 PM]
6/1/202072FILED from Appellees Sanofi, Aventisub LLC, Regeneron Pharmaceuticals Inc. and Sanofi-Aventis U.S. LLC. Title: CONFIDENTIAL RESPONSE BRIEF. Service: 06/01/2020 by email. [698413] [20-1074] This document is non-compliant. See Doc. No.[74] [Calvin Shank] [Entered: 06/01/2020 07:14 PM]
6/1/2020Amended Certificate of Interest for Appellees Sanofi, Aventisub LLC, Regeneron Pharmaceuticals Inc. and Sanofi-Aventis U.S. LLC. Service: 06/01/2020 by email. [698412] [20-1074] [Calvin Shank] [Entered: 06/01/2020 07:07 PM]
6/1/2020Amended Certificate of Interest for Appellees Sanofi, Aventisub LLC, Regeneron Pharmaceuticals Inc. and Sanofi-Aventis U.S. LLC. Service: 06/01/2020 by email. [698114] [20-1074] [Calvin Shank] [Entered: 06/01/2020 10:13 AM]
5/29/202069
  • Motion to Withdraw as CounselGranted
**TEXT ONLY** ORDER granting motion to withdraw Katherine Nicole Clouse as counsel [68] filed by Appellants Amgen USA, Inc., Amgen Inc., and Amgen Manufacturing, Limited. Service as of this date by the Clerk of Court. This order has been issued without an attached document and is official and binding. [697752] [JAL] [Entered: 05/29/2020 09:09 AM]
5/28/2020
  • Motionby Π
MOTION of Appellants Amgen Inc., Amgen Manufacturing, Limited and Amgen USA, Inc. to withdraw counsel Katherine Nicole Clouse [Consent: unopposed]. Service: 05/28/2020 by clerk, email. [697666] [20-1074] [William Gaede] [Entered: 05/28/2020 05:55 PM]
3/25/2020AMICUS BRIEF FILED for Amici Curiae Bristol-Myers Squibb Company and Merck Sharp & Dohme Corp. Pages: 23. Service: 02/28/2020 by email. [681657] [Accepted pursuant to order [66]] [JAL] [Entered: 03/25/2020 12:58 PM]
3/25/2020
  • Motion to File BriefGranted
ORDER filed granting motion for leave to file an amicus curiae brief [61]. The brief is accepted for filing.. Service as of this date by the Clerk of Court. [681640] [NL] [Entered: 03/25/2020 12:27 PM]
3/10/2020
  • Motion to Extend Time to File BriefGranted
ORDER granting motion to extend time to file brief [64] filed by Appellees. The response brief is due 06/01/2020. Service as of this date by the Clerk of Court. [677592] [NL] [Entered: 03/10/2020 02:26 PM]
3/5/2020
  • Motionby Δ
MOTION of Appellees Sanofi, Aventisub LLC, Regeneron Pharmaceuticals Inc. and Sanofi-Aventis U.S. LLC to extend the time to 06/01/2020 to file Response/Reply [Consent: unopposed]. Service: 03/05/2020 by email. [676760] [20-1074] [Matthew Wolf] [Entered: 03/05/2020 06:53 PM]
2/28/2020Entry of appearance for William H. Milliken as of counsel for Bristol-Myers Squibb Co. and Merck Sharp & Dohme Corp.. Service: 02/28/2020 by email. [675347] [20-1074] [William Milliken] [Entered: 02/28/2020 06:43 PM]
2/28/2020Entry of appearance for Eldora L. Ellison as of counsel for Bristol-Myers Squibb Co. and Merck Sharp & Dohme Corp.. Service: 02/28/2020 by email. [675346] [20-1074] [Eldora Ellison] [Entered: 02/28/2020 06:41 PM]
2/28/2020
  • Motion
MOTION of Bristol-Myers Squibb Co. and Merck Sharp & Dohme Corp. for leave to file an amicus curiae brief [Consent: unopposed]. Service: 02/28/2020 by email. [675345] [20-1074] [Kristina Caggiano Kelly] [Entered: 02/28/2020 06:38 PM]
2/28/2020Certificate of Interest for Bristol-Myers Squibb Co. and Merck Sharp & Dohme Corp.. Service: 02/28/2020 by email. [675344] [20-1074] [Kristina Caggiano Kelly] [Entered: 02/28/2020 06:34 PM]
2/28/2020Entry of appearance for Kristina Caggiano Kelly as of counsel for Bristol-Myers Squibb Co. and Merck Sharp & Dohme Corp.. Service: 02/28/2020 by email. [675343] [20-1074] [Kristina Caggiano Kelly] [Entered: 02/28/2020 06:31 PM]
2/28/2020Entry of appearance for Jorge A. Goldstein as principal counsel for Bristol-Myers Squibb Co. and Merck Sharp & Dohme Corp.. Service: 02/28/2020 by email. [675341] [20-1074] [Kristina Caggiano Kelly] [Entered: 02/28/2020 06:29 PM]
2/27/2020Amended Entry of appearance for Victoria Reines as of counsel for Appellees Sanofi, Sanofi-Aventis U.S. LLC, Aventisub LLC and Regeneron Pharmaceuticals Inc.. Service: 02/27/2020 by email. [674772] [20-1074] [Victoria Reines] [Entered: 02/27/2020 12:15 PM]
2/25/202056REMINDER: All counsel of record are reminded of their responsibility per Fed. Cir. R. 47.3 to promptly submit an amended Entry of Appearance and/or update their contact information via PACER as information changes during the pendency of the appeal. Failure to comply with these Rules may delay the timely processing of your case or result in adverse action. [674067] [JAL] [Entered: 02/25/2020 02:29 PM]
2/21/2020MODIFIED ENTRY: OPENING BRIEF FILED for Appellants Amgen Inc., Amgen Manufacturing, Limited, and Amgen USA, Inc. Number of Pages: 69. Service: 02/21/2020 by email. Unless ordered otherwise, any responsive deadline runs from the date of service of this brief. See Fed. Cir. R. 31. [673458] --[Edited 02/25/2020 by JAL - Compliance review complete] [Jeffrey Lamken] [Entered: 02/21/2020 07:26 PM]
2/21/2020Amended Entry of appearance for Jeffrey A. Lamken as principal counsel for Appellants Amgen Inc., Amgen Manufacturing, Limited and Amgen USA, Inc.. Service: 02/21/2020 by email. [673457] [20-1074] [Jeffrey Lamken] [Entered: 02/21/2020 07:21 PM]
2/21/2020Amended Entry of appearance for Michael G. Pattillo, Jr. as of counsel for Appellants Amgen Inc., Amgen Manufacturing, Limited and Amgen USA, Inc.. Service: 02/21/2020 by email. [673456] [20-1074] [Michael Pattillo] [Entered: 02/21/2020 07:18 PM]
2/21/2020Amended Entry of appearance for Sarah J. Newman as of counsel for Appellants Amgen Inc., Amgen Manufacturing, Limited and Amgen USA, Inc.. Service: 02/21/2020 by email. [673455] [20-1074] [Sarah Newman] [Entered: 02/21/2020 07:15 PM]
2/21/2020Entry of appearance for Steven D. Tang as of counsel for Appellants Amgen Inc., Amgen Manufacturing Limited, Amgen Manufacturing, Limited and Amgen USA, Inc.. Service: 02/21/2020 by email. [673418] [20-1074] [Steven Tang] [Entered: 02/21/2020 05:13 PM]
2/21/2020Entry of appearance for Emily Curtis Johnson as of counsel for Appellants Amgen Inc., Amgen Manufacturing Limited, Amgen Manufacturing, Limited and Amgen USA, Inc.. Service: 02/21/2020 by email. [673402] [20-1074] [Emily Johnson] [Entered: 02/21/2020 04:44 PM]
2/21/2020Entry of appearance for Stuart Watt as of counsel for Appellants Amgen Inc., Amgen Manufacturing Limited, Amgen Manufacturing, Limited and Amgen USA, Inc.. Service: 02/21/2020 by email. [673358] [20-1074] [Stuart Watt] [Entered: 02/21/2020 03:38 PM]
2/21/2020Corrected Entry of appearance for Erica Olson as of counsel for Appellants Amgen Inc., Amgen Manufacturing Limited, Amgen Manufacturing, Limited and Amgen USA, Inc.. Service: 02/21/2020 by email. [673356] [20-1074] [Erica Olson] [Entered: 02/21/2020 03:31 PM]
2/21/2020Entry of appearance for Erica Olson as principal counsel for Appellants Amgen Inc., Amgen Manufacturing Limited, Amgen Manufacturing, Limited and Amgen USA, Inc.. Service: 02/21/2020 by email. [673309] [20-1074] [Erica Olson] [Entered: 02/21/2020 02:38 PM]
2/21/2020Entry of appearance for Wendy A. Whiteford as of counsel for Appellants Amgen Inc., Amgen Manufacturing Limited and Amgen USA, Inc.. Service: 02/21/2020 by email. [673303] [20-1074] [Wendy Whiteford] [Entered: 02/21/2020 02:34 PM]
2/7/2020
  • Motion to Withdraw as CounselGranted
ORDER granting motion to withdraw Anne W. Pearlman as counsel [44] filed by Appellees Sanofi, Aventisub LLC, Regeneron Pharmaceuticals Inc., and Sanofi-Aventis U.S. LLC. Service as of this date by the Clerk of Court. [669246] [JAL] [Entered: 02/07/2020 09:38 AM]
2/5/2020
  • Motion
MOTION of Appellees Sanofi, Aventisub LLC, Regeneron Pharmaceuticals Inc. and Sanofi-Aventis U.S. LLC to withdraw counsel Anne W. Pearlman [Consent: not addressed]. Service: 02/05/2020 by email. [668683] [20-1074] [Anne Pearlman] [Entered: 02/05/2020 02:19 PM]
1/16/2020Entry of appearance for Lauren Martin as of counsel for Appellant Amgen Inc.. Service: 01/16/2020 by email, US mail. [663717] [20-1074] [Lauren Martin] [Entered: 01/16/2020 10:19 AM]
1/15/202042
  • Motion to Extend Time to File BriefGranted
**TEXT ONLY** ORDER granting motion to extend time to file brief [41] filed by Appellants Amgen USA, Inc., Amgen Inc., and Amgen Manufacturing, Limited. The opening brief is due 02/21/2020. Service as of this date by the Clerk of Court. This order has been issued without an attached document and is official and binding. [663096] [JAL] [Entered: 01/15/2020 09:33 AM]
1/14/2020
  • Motion to Extend Time to File Briefby Π
MOTION of Appellants Amgen Inc., Amgen Manufacturing, Limited and Amgen USA, Inc. to extend the time to 02/21/2020 to file the Opening Brief. [Consent: unopposed]. Service: 01/14/2020 by email. [662979] [20-1074] [Jeffrey Lamken] [Entered: 01/14/2020 04:45 PM]
1/14/2020Amended Certificate of Interest for Appellants Amgen Inc., Amgen Manufacturing, Limited and Amgen USA, Inc.. Service: 01/14/2020 by email. [662977] [20-1074] [Jeffrey Lamken] [Entered: 01/14/2020 04:41 PM]
12/23/2019Corrected Entry of appearance for Christopher B. Mead as principal counsel for Appellants Amgen Inc., Amgen Manufacturing Limited and Amgen USA, Inc.. Service: 12/23/2019 by email. [658512] [20-1074] [Christopher Mead] [Entered: 12/23/2019 02:07 PM]
12/16/201938
  • Motion to Extend Time to File BriefGranted
**TEXT ONLY** ORDER granting motion to extend time to file brief [37] filed by Appellants Amgen USA, Inc., Amgen Inc., and Amgen Manufacturing, Limited. The opening brief is due 01/22/2020. Service as of this date by the Clerk of Court. This order has been issued without an attached document and is official and binding. [656657] [JAL] [Entered: 12/16/2019 09:16 AM]
12/13/2019
  • Motion to Extend Time to File Briefby Π
MOTION of Appellants Amgen Inc., Amgen Manufacturing, Limited and Amgen USA, Inc. to extend the time to 01/22/2020 to file the Opening Brief. [Consent: unopposed]. Service: 12/13/2019 by email. [656581] [20-1074] [Jeffrey Lamken] [Entered: 12/13/2019 04:41 PM]
12/11/201936Notice to counsel for Appellants Amgen Inc., Amgen Manufacturing, Limited, and Amgen USA, Inc.: The record of this case indicates that the Corrected Entry of Appearance for C. Mead has not been filed. Service as of this date by the Clerk of Court. [655710] [JAL] [Entered: 12/11/2019 03:02 PM]
11/18/201935Official caption revised in response to Notice of Objection to the Official Caption [5]. The official caption is reflected on the electronic docket under the listing of the parties and counsel. Service as of this date by the Clerk of Court. [649867] [JAL] [Entered: 11/18/2019 09:05 AM]
11/14/2019NOTICE OF NON-COMPLIANCE: The submission of Appellants Amgen Inc., Amgen Manufacturing Limited, and Amgen USA, Inc., Entry of Appearance - C. Mead [33], is not in compliance with the rules of this court (see attached). Compliant document is due on 11/21/2019. Service as of this date by the Clerk of Court. [649464] [JAL] [Entered: 11/14/2019 04:18 PM]
11/14/2019Entry of appearance for Christopher B. Mead as of counsel for. Service: 11/14/2019 by email. [649322] [20-1074] This document is non-compliant. See Doc No.[34] [Christopher Mead] [Entered: 11/14/2019 01:43 PM]
11/14/2019Corrected Entry of appearance for William G. Gaede III as of counsel for Appellants Amgen Inc., Amgen Manufacturing Limited and Amgen USA, Inc.. Service: 11/14/2019 by clerk, email. [649316] [20-1074] [William Gaede] [Entered: 11/14/2019 01:32 PM]
11/14/2019Entry of appearance for Katherine Nicole Clouse as of counsel for Appellant Amgen Inc.. Service: 11/14/2019 by clerk, email. [649296] [20-1074] [Katherine Clouse] [Entered: 11/14/2019 01:09 PM]
11/14/2019Entry of appearance for Katherine Nicole Clouse as of counsel for Appellant Amgen Inc.. Service: 11/14/2019 by clerk, email. [649293] [20-1074] [Sarah Columbia] [Entered: 11/14/2019 01:00 PM]
11/14/2019Entry of appearance for Sarah Chapin Columbia as of counsel for Appellant Amgen Inc.. Service: 11/14/2019 by clerk, email. [649291] [20-1074] [Sarah Columbia] [Entered: 11/14/2019 12:58 PM]
11/14/2019NOTICE OF NON-COMPLIANCE: The submission of Amgen Inc., Amgen Manufacturing Limited, and Amgen USA, Inc., Entry of Appearance - W. Gaede III [27], is not in compliance with the rules of this court (see attached). Compliant document due 11/21/2019. Service as of this date by the Clerk of Court. [649092]--[Edited 11/14/2019 by MJL to correct filed date] [JAL] [Entered: 11/13/2019 04:38 PM]
11/11/2019Entry of appearance for William G. Gaede, III as of counsel for Appellants Amgen Inc., Amgen Manufacturing Limited and Amgen USA, Inc. Service: 11/11/2019 by clerk, email. [648411] [20-1074] This document is non-compliant. See Doc No.[28] [William Gaede] [Entered: 11/11/2019 12:11 PM]
11/8/2019Entry of appearance for Keith R. Hummel as of counsel for Appellants Amgen Inc., Amgen Manufacturing Limited and Amgen USA, Inc.. Service: 11/08/2019 by email. [648368] [20-1074] [Keith Hummel] [Entered: 11/08/2019 05:01 PM]
11/8/201925REMINDER: All counsel of record are reminded of their responsibility per Fed. Cir. R. 47.3 to promptly submit an amended Entry of Appearance and/or update their contact information through the PACER Service Center as information changes during the pendency of the appeal. Failure to comply with these Rules may delay the timely processing of your case or result in adverse action. [648262]--[Edited 11/08/2019 by JAL to amend docket text] [JAL] [Entered: 11/08/2019 03:15 PM]
11/7/2019Entry of appearance for Victoria Reines as of counsel for Appellees Sanofi, Sanofi-Aventis U.S. LLC, Aventisub LLC and Regeneron Pharmaceuticals Inc.. Service: 11/07/2019 by email. [647920] [20-1074] [Victoria Reines] [Entered: 11/07/2019 04:51 PM]
11/7/2019Entry of appearance for Deborah Fishman as of counsel for Appellees Sanofi, Sanofi-Aventis U.S. LLC, Aventisub LLC and Regeneron Pharmaceuticals Inc.. Service: 11/07/2019 by email. [647919] [20-1074] [Deborah Fishman] [Entered: 11/07/2019 04:47 PM]
11/7/2019Entry of appearance for David K. Barr as of counsel for Appellees Sanofi, Sanofi-Aventis U.S. LLC, Aventisub LLC and Regeneron Pharmaceuticals Inc.. Service: 11/07/2019 by email. [647913] [20-1074] [David Barr] [Entered: 11/07/2019 04:41 PM]
11/7/2019Entry of appearance for Daniel L. Reisner as of counsel for Appellees Sanofi, Sanofi-Aventis U.S. LLC, Aventisub LLC and Regeneron Pharmaceuticals Inc.. Service: 11/07/2019 by email. [647907] [20-1074] [Daniel Reisner] [Entered: 11/07/2019 04:37 PM]
11/7/2019Entry of appearance for Anne Pearlman as of counsel for Appellees Sanofi, Sanofi-Aventis U.S. LLC, Aventisub LLC and Regeneron Pharmaceuticals Inc.. Service: 11/07/2019 by email. [647903] [20-1074] [Anne Pearlman] [Entered: 11/07/2019 04:32 PM]
11/7/2019Entry of appearance for Stephanie Donahue as of counsel for Appellees Sanofi, Sanofi-Aventis U.S. LLC and Aventisub LLC. Service: 11/07/2019 by email. [647898] [20-1074] [Anne Pearlman] [Entered: 11/07/2019 04:28 PM]
11/7/2019Entry of appearance for Lynda Q. Nguyen as of counsel for Appellee Regeneron Pharmaceuticals Inc.. Service: 11/07/2019 by email. [647893] [20-1074] [Anne Pearlman] [Entered: 11/07/2019 04:25 PM]
11/7/2019Entry of appearance for James L. Higgins as of counsel for Appellants Amgen Inc., Amgen Manufacturing Limited and Amgen USA, Inc.. Service: 11/07/2019 by email. [647889] [20-1074] [James Higgins] [Entered: 11/07/2019 04:23 PM]
11/7/2019Entry of appearance for Larry Coury as of counsel for Appellee Regeneron Pharmaceuticals Inc.. Service: 11/07/2019 by email. [647886] [20-1074] [Anne Pearlman] [Entered: 11/07/2019 04:22 PM]
11/7/2019Entry of appearance for Melanie K. Sharp as of counsel for Appellants Amgen Inc., Amgen Manufacturing Limited and Amgen USA, Inc.. Service: 11/07/2019 by email. [647876] [20-1074] [Melanie Sharp] [Entered: 11/07/2019 04:14 PM]
11/7/2019Entry of appearance for Matthew W. Wolf as principal counsel for Appellees Sanofi, Sanofi-Aventis U.S. LLC, Aventisub LLC and Regeneron Pharmaceuticals Inc.. Service: 11/07/2019 by email. [647871] [20-1074] [Matthew Wolf] [Entered: 11/07/2019 04:05 PM]
11/7/2019Certificate of Interest for Appellees Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi and Sanofi-Aventis U.S. LLC. Service: 11/07/2019 by email. [647840] [20-1074] [Calvin Shank] [Entered: 11/07/2019 03:19 PM]
11/7/2019Docketing Statement for the Appellees Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi and Sanofi-Aventis U.S. LLC. Service: 11/07/2019 by email. [647838] [20-1074] [Calvin Shank] [Entered: 11/07/2019 03:18 PM]
11/7/2019Entry of appearance for C. Alex Shank as of counsel for Appellees Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi and Sanofi-Aventis U.S. LLC. Service: 11/07/2019 by email. [647836] [20-1074] [Calvin Shank] [Entered: 11/07/2019 03:16 PM]
11/7/2019Entry of appearance for Nathan S. Mammen as of counsel for Appellees Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi and Sanofi-Aventis U.S. LLC. Service: 11/07/2019 by email. [647834] [20-1074] [Calvin Shank] [Entered: 11/07/2019 03:15 PM]
11/7/2019Entry of appearance for George W. Hicks as of counsel for Appellees Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi and Sanofi-Aventis U.S. LLC. Service: 11/07/2019 by email. [647833] [20-1074] [Calvin Shank] [Entered: 11/07/2019 03:14 PM]
11/7/2019Entry of appearance for Sara E. Margolis as of counsel for Appellants Amgen Inc., Amgen Manufacturing Limited and Amgen USA, Inc.. Service: 11/07/2019 by email. [647797] [20-1074] [Sara Margolis] [Entered: 11/07/2019 02:19 PM]
11/7/2019Entry of appearance for Sarah J. Newman as of counsel for Appellants Amgen Inc., Amgen Manufacturing Limited and Amgen USA, Inc.. Service: 11/07/2019 by email. [647791] [20-1074] [Sarah Newman] [Entered: 11/07/2019 02:14 PM]
11/7/2019Entry of appearance for Michael G. Pattillo, Jr. as of counsel for Appellants Amgen Inc., Amgen Manufacturing Limited and Amgen USA, Inc.. Service: 11/07/2019 by email. [647789] [20-1074] [Michael Pattillo] [Entered: 11/07/2019 02:10 PM]
11/7/2019Objection to the official caption pursuant to Rule 12 Practice Note by Appellants Amgen Inc., Amgen Manufacturing Limited and Amgen USA, Inc.. Service: 11/07/2019 by email. [647785] [20-1074] [Jeffrey Lamken] [Entered: 11/07/2019 02:08 PM]
11/7/2019Docketing Statement for the Appellants Amgen Inc., Amgen Manufacturing Limited and Amgen USA, Inc.. Service: 11/07/2019 by email. [647781] [20-1074] [Jeffrey Lamken] [Entered: 11/07/2019 02:06 PM]
11/7/2019Certificate of Interest for Appellants Amgen Inc., Amgen Manufacturing Limited and Amgen USA, Inc.. Service: 11/07/2019 by email. [647779] [20-1074] [Jeffrey Lamken] [Entered: 11/07/2019 02:05 PM]
11/7/2019Entry of appearance for Jeffrey A. Lamken as principal counsel for Appellants Amgen Inc., Amgen Manufacturing Limited and Amgen USA, Inc.. Service: 11/07/2019 by email. [647778] [20-1074] [Jeffrey Lamken] [Entered: 11/07/2019 02:03 PM]
10/24/2019Appeal docketed. Received: 10/23/2019. [644354]
Entry of Appearance is due 11/07/2019. Certificate of Interest is due on 11/07/2019. Docketing Statement is due 11/07/2019. Appellant's brief is due 12/23/2019. [JAL] [Entered: 10/24/2019 10:10 AM]